OBJECTIVE: Neurons in the area postremaanucleus of the solitary tract (APaNTS) region mediate amylin's anorectic effect elicited by a single intraperitoneal (i.p.) injection of a low dose (5 mgakg). Here, we tested if a sustained elevation in amylin levels which was achieved by chronic amylin infusion reduces food intake by acting in the APaNTS region or, possibly, at other brain sites. Further, we tested the role of the APaNTS region in mediating the anorectic effects of high doses of amylin and its receptor agonist salmon calcitonin (sCT) after an acute single injection. DESIGN: Amylin (2 mgakgah) was chronically infused i.p. by osmotic minipumps in APaNTS-lesioned (AP-X) or sham-lesioned (SHAM) rats. For the acute experiments, amylin or sCT was injected i.p. at doses of 0.5 (only sCT), 5 or 50 mgakg. Food intake was measured by a computerized system. Body weight was assessed by manually weighing the rats. RESULTS: Amylin signi®cantly reduced cumulative food intake for about 7 days in SHAM but not in AP-X rats. Amylin's effect in SHAM rats was mainly due to a reduction of the size of nocturnal meals (eg average meal size during the ®rst four dark phases; SHAM, NaCl 4.1 AE 0.6 vs amylin 2.6 AE 0.4 g; n 6, P`0.05; AP-X, 2.6 AE 0.3 vs 3.7 AE 0.3) while light phase food intake was unaffected. Body weight gain over the whole 14 day infusion period was reduced by amylin in SHAM (NaCl 61 AE 6 vs amylin 46 AE 4 g; P`0.05) but not in AP-X rats (54 AE 4 vs 62 AE 4). After single injection, the anorectic effect of high doses of amylin and sCT (50 mgakg) was attenuated, but not abolished, in AP-X rats. CONCLUSION: We conclude that, under our experimental conditions, neurons in the APaNTS region are necessary for chronically elevated peripheral amylin to reduce food intake in rats. High doses of amylin, however, may be able to overrun these receptors and reduce feeding by acting at other brain sites.
Introduction
The pancreatic peptide amylin is regarded as a novel satiety peptide. 1 Amylin reduces food intake in rats and mice after peripheral and central administration, 1 ± 4 and its main effect after a single injection is to promote meal-ending satiety. 1 In addition to its function as a short-term satiety signal, amylin also exerts a long-term anorectic effect and thus may act as a lipostatic signal 5 because chronic administration of amylin reduces food intake and body weight in rats. 6, 7 Second, central administration of a low amylin dose elicits a long-lasting anorectic action and a reduction in body weight, 5 and third, subthreshold doses of amylin and insulin, which is involved in the long-term control of food intake, 8 interact to reduce food intake. 9 Finally, because amylin-de®cient knockout mice gain body weight faster than wildtype controls, 10 it was hypothesized that amylin may act as a long-term regulator of energy balance 5 in concert with insulin and leptin. 8 Previous studies have clearly established that the area postremaanucleus of the solitary tract (APaNTS) region mediates amylin's satiety effect induced by a single intraperitoneal (i.p.) injection. 3, 11 Because amylin's anorectic effect was abolished in rats lesioned in the APaNTS region (AP-X rats 3, 11 ) while chemical ablation of sensory afferent nerves with capsaicin left amylin's effect unaltered, 4, 12 AP neurons seem to directly mediate amylin's satiety effect. Apart from the APaNTS region, amylin receptors have also been found in other brain areas involved in the control of food intake such as the lateral parabrachial nucleus, the central nucleus of the amygdala and the hypothalamus. 13 In contrast to the amylin receptors in the APaNTS region, however, the role of amylin receptors at other brain sites in mediating peripheral amylin's anorectic effect is unclear. We hypothesized that, while amylin's short-term satiety effect is predominantly mediated by APaNTS neurons, 3 ,11 the sustained anorectic effect induced by chronically elevated amylin levels may also be mediated by amylin receptors at other brain sites. These receptors may perhaps not be as readily accessible as APaNTS neurons for circulating amylin and therefore, after a single acute injection of a low dose of amylin, 1, 3 the time required for peripheral amylin to reach these receptors may perhaps not suf®ce because amylin is rapidly degraded in the plasma.
14 During long-term elevation of plasma amylin levels, amylin receptors, eg in the forebrain, might however be reached by amylin.
In the present study, we tested this hypothesis by producing a long-term elevation of plasma amylin levels using different approaches, ®rst a chronic i.p. infusion of amylin, and second a single i.p. injection of a high dose of amylin to elevate plasma amylin levels for at least 2 h above fasting levels. 14 In the last experiment, we tested the effect of the related peptide salmon calcitonin (sCT) on food intake because sCT produces a long lasting reduction in food intake at least in part via amylin receptors. 15 
Materials and methods
Adult male Sprague ± Dawley rats (OFA; BRL, Fu Èllinsdorf, Switzerland) were used for the experiments. Rats were housed individually in specially designed plexiglass cages in which a tunnel (length 15 cm; diameter 6.5 cm) provided access to spillage-resistant feeding cups.
1 Rats were adapted to the housing conditions (room temperature 21 AE 1 C; arti®cial 12 ha12 h lightadark cycle (lights on 08:00 h)) for at least 2 weeks before surgery. Rats were fed a medium fat diet (18% waw fat) which was available ad libitum except during food deprivation just before surgery. Water was always available ad libitum.
Surgery
Before surgery, mean body weight of all rats was approximately 280 ± 290 g. Rats were randomly allocated into a group of rats to be lesioned in the area postremaanucleus of the solitary tract region (APaNTS) or a group of shamoperated controls (SHAM rats). Nineteen rats were lesioned (AP-X rats) in the APaNTS by a procedure described by McGlone et al. 3, 16 After exposure, the AP was blotted with cotton ear swabs and then thermally lesioned with a triangular copper wire (approximately 0.7 mm). In 14 SHAM rats, the procedure was identical except for actually thermally lesioning the APaNTS.
Veri®cation of the APaNTS lesion
The APaNTS lesion was ®rst veri®ed by a functional test performed with all AP-X and SHAM rats. Since amylin's anorectic effect after intraperitoneal (i.p.) injection is markedly reduced in AP-X rats, 3,11 a similar experiment was performed with the group of rats used in the present study. Rats were food deprived for 24 h before injection. Amylin (5 mgakg i.p.) or an equal volume of 0.9% NaCl (2 mlakg) was injected at dark onset. This experiment was performed in counterbalanced order (see Experiment 1). Due to technical constraints, ie because the computerized measuring system only allowed continuous assessment of food intake in 24 rats, not all rats used in Experiment 1 could be used for the subsequent chronic infusion study. From all 19 animals subjected to the APaNTS lesion, 12 AP-X rats were used in the chronic infusion experiment. Amylin did not produce an anorectic response ( AE 0.4 g vs control) in these rats. SHAM rats showed a strong response to the amylin injection (see Experiment 1) and 12 of the 14 SHAM rats were used in the chronic infusion experiment.
After completion of all feeding experiments, AP-X and SHAM rats were sacri®ced and their brains analyzed histologically. Slides for staining were prepared by routine procedures. The APaNTS region was examined by light microscopy and the extent of the lesion was evaluated in all rats. Histological examination con®rmed that the APaNTS region was lesioned in all 12 AP-X rats but in none of the 12 SHAM rats included in the chronic infusion study, and all these rats were included in the statistical evaluation of the results of this experiment.
Implantation of osmotic minipumps
Rats were allowed to recover for about 5 ± 6 weeks after the APaNTS lesion before the osmotic minipumps were implanted. After 12 h food deprivation, pumps were implanted under ketamineaxylazine anesthesia into the abdominal cavity for i.p. delivery of amylin. A 1.5 ± 2 cm incision in the linea alba allowed access to the abdominal cavity. After implantation of the pumps, the incision was closed with resorbable suture material (Vicryl; Ethicon, Norderstedt, FRG). Pumps were implanted on day one of the experiment during the ®rst 3 h of the light phase (light phase of day 1).
Minipumps with a mean pumping rate of approximately 0.5 mlah were used (model 2002, nominal reservoir volume 200 ml; lot no. 181843; Alzet Inc., Palo Alto, CA, USA). Scheduled duration of infusion was for a minimum of 14 days. The calculated delivery rate for amylin was 2 mgakgah. At the time of surgery, AP-X rats had reached a body weight of about 310 AE 9 vs 365 AE 4 g in SHAM rats. Average body weight over the whole 14 d infusion period was estimated to be 350 g in AP-X and 400 g in SHAM rats. These values served to calculate the respective amount of amylin to ®ll the pumps (2 mgakgah). Before surgery, AP-X and SHAMrats were divided into two groups based on their body weight and basal food intake which was measured in the dark phase preceding the surgery. Half of the AP-X (n 6) and half of the SHAM (n 6) rats received amylin while the remaining rats (six AP-X; six SHAM) served as respective saline controls.
Data recording
The spillage-resistant feeding cups were ®xed on electronic precision balances whose outputs were continuously monitored to compute cumulative food intake and meal patterns. Meals were de®ned using a minimum meal size criterion of 0.3 g, a minimum meal duration criterion of 1 min, and a minimum intermeal interval (IMI) criterion of 15 min, measured from the last measured intake of a meal. 1 Using these criteria, about 95% of total food intake was resolved into meals. Body weight of rats was assessed by manually weighing the rats.
Measurement of food intake started immediately after the implantation of the minipumps for the remainder of the ®rst light phase. Since the rats recovered from anesthesia over a period of several hours, data from the ®rst light phase were not analyzed in detail. Beginning with the ®rst dark phase after implantation, food intake was analyzed on a daily basis (light phase food intake; dark phase food intake; size of individual meals; average meal size, etc). Food intake data were also pooled to calculate average and total food intake of days 1 ± 6 and 7 ± 14 of the experiment. Average meal size during these periods was calculated.
Single i.p. injection of amylin (50 mgakg) and salmon calcitonin (sCT; 0.5, 5 or 50 mgakg) After completion of the chronic infusion experiment, the 12 AP-X and 12 SHAM rats used in the chronic infusion study were subjected to further experiments where a high dose of amylin (50 mgakg) was administered by a single acute i.p. injection. Considering the pharmacokinetics of amylin, 14 we aimed at elevating the plasma amylin level for at least 2 h above fasting levels with this approach. Similar to recent experiments, 3, 11 rats were food deprived for 24 h before injection. Amylin (50 mgakg i.p.) or an equal volume of 0.9% NaCl (1 mlakg) were injected at dark onset. Additional experiments were performed with the amylin receptor agonist sCT 15 (0.5, 5 or 50 mgakg i.p.) because sCT reduces food intake at least in part via amylin receptors. Due to irreversible binding to these receptors, however, sCT's duration of action is prolonged compared to that of amylin. 15 
Statistics
Results are presented as means AE s.e. The in¯uence of the APaNTS lesion on the effect of amylin on food intake and on body weight was investigated using two-factor analysis of variance (ANOVA). An ordinary analysis of variance (ANOVA) with the Student ± Newman ± Keuls post hoc test was used to assess the effect of amylin treatment. In all cases, a value of P`0.05 was considered signi®cant.
Results
Experiment 1: effect of amylin on food intake and body weight after single amylin injection (5 mgakg i.p.) in AP-X and SHAM rats Amylin (5 mgakg i.p.) signi®cantly reduced cumulative food intake for 2 h in SHAM rats but not in AP-X rats ( Figure 1 ). This test con®rmed the successful lesioning of the APaNTS region in AP-X rats. Due to technical restraints, only 12 of 19 AP-X and 12 of 14 SHAM rats were used in the subsequent chronic infusion experiment (see Materials and methods).
Experiment 2: effect of amylin on food intake and body weight during chronic amylin infusion in AP-X and SHAM rats Total food intake in the ®rst dark phase was lower in AP-X than in SHAM rats (P`0.05) but there was no difference between amylin-treated and the respective saline-treated control rats (Figure 2A and B) . From day 2 to day 6, amylin produced a potent anorectic response in SHAM rats. Amylin's anorectic effect was most marked during the dark phase while light phase food intake generally remained unchanged Figure 1 In¯uence of amylin (5 mgakg) injected i.p. at dark onset on cumulative food intake in 24 h food deprived area postremaanucleus of the solitary tract lesioned (AP-X; n 19) and sham lesioned (SHAM; n 14) rats compared with respective saline controls. ***Signi®cant difference between amylin-treated and respective control rats (ANOVA with paired Student's t-test as post hoc test; P`0.001).
APaNTS lesion abolishes amylin's chronic anorectic effect TA Lutz et al ( Figure 2A ). The reduction in dark phase food intake induced by amylin was most pronounced during the ®rst 4 h of the dark phase while food intake during the remaining 8 h of the dark phase was only marginally affected (data not shown).
In contrast to SHAM rats, no anorectic response was produced by amylin in AP-X rats. Food intake rather tended to be higher in amylin-treated AP-X rats than in the respective controls ( Figure 2B ). This tendency was more pronounced in the dark than in the light phase ( Figure 2B ). On the fourth day of infusion, food intake during the ®rst 4 h of the dark phase was signi®cantly higher in the amylintreated AP-X rats than in the respective controls (data not shown). The effect of the APaNTS lesion to attenuate amylin's anorectic effect was signi®cant (P`0.05) during the dark phases of infusion days 2, 4, 5 and 6.
The sustained effect of amylin to reduce food intake in SHAM rats was also re¯ected in the pooled food intake data from days 1 to 6. Amylin reduced total 6 day food intake in SHAM rats by about 20% (Table 1 ). The same holds true for average daily food intake on days 1 ± 6. Amylin's effect was restricted to the dark phase (Table 1) while light phase food intake remained unaffected. The APaNTS lesion completely abolished amylin's anorectic effect (P`0.05) because food intake pooled from days 1 to 6 was not reduced by amylin in AP-X rats. As for individual days, there was rather a tendency for amylin to increase food intake in AP-X rats ( Table 1 ). The anorectic effect of amylin as observed in SHAM rats on days 1 ± 6 was almost completely accounted for by a reduction in meal size during the dark phase and a correspondent reduction in meal duration (eg average dark phase meal size; Table  1 ). In contrast, a signi®cant increase in average meal size in amylin-treated AP-X rats as compared to the respective controls (Table 1) explains the tendency for amylin to enhance feeding in AP-X rats. Although amylin appeared to slightly affect the number of dark phase meals and the duration of the average intermeal intervals in SHAM rats, none of these effects reached the level of signi®cance. Similarly, none of these meal parameters was signi®cantly affected by amylin in AP-X rats (data not shown).
For the remainder of the infusion period (days 7 ± 14), amylin failed to reduce food intake in SHAM rats. Although there was a tendency for amylin to decrease feeding on some individual days, there was no overall effect on cumulative or average food intake pooled for days 7 ± 14 (Table 2) . Similarly, average dark phase or light phase meal size remained unaffected. During days 7 ± 14, amylin tended to increase feeding in AP-X rats on some days, but there was no overall effect of amylin on cumulative or average food intake in AP-X rats (Table 2) . However, amylin signi®cantly increased average light phase meal size and tended to increase average dark phase meal size during this period in AP-X rats ( Table 2) . Meal number was slightly but not signi®cantly reduced.
Amylin's differing effects on food intake in SHAM compared with AP-X rats were also mirrored by its effect on the rate of body weight gain. The APaNTS lesion signi®cantly Figure 2 In¯uence of chronic intraperitoneal amylin infusion (2 mga kgah) on cumulative food intake during the dark phases (DP) and light phases (LP) on days 1 ± 6 of the infusion in sham lesioned (SHAM; A) and area postremaanucleus of the solitary tract lesioned (AP-X; B) rats. *Signi®cant difference between amylin-treated and control rats within SHAM or AP-X rats, respectively (P`0.05; n 6 for all groups; Student ± Newman ± Keuls post hoc test). Table 1 In¯uence of chronic intraperitoneal amylin infusion (2 mgakgah) on food intake in area postremaanucleus of the solitary tract lesioned (AP-X) and sham lesioned (SHAM) rats from days 1 to 6 of the infusion period (total 6 day food intake; average daily food intake; average dark phase food intake; average light phase food intake; average size of dark phase meals; all measures in grams) SHAM rats AP-X rats NaCl Amylin NaCl Amylin Signi®cant difference between amylin and NaCl within SHAM or AP-X rats, respectively (P`0.05; n 6 for all groups; Student ± Newman ± Keuls post hoc test).
APaNTS lesion abolishes amylin's chronic anorectic effect TA Lutz et al (P`0.05) attenuated amylin's effect on body weight gain because amylin signi®cantly slowed down the rate of body weight gain (715 g) in SHAM rats over the whole 14 day observation period (61 AE 6 vs 46 AE 4 g; P`0.05), while amylin-treated AP-X rats rather tended to increase body weight ( 8 g) slightly faster than saline-treated AP-X rats (54 AE 4 vs 62 AE 4; not signi®cant).
Experiment 3: effect of amylin on food intake and body weight after single amylin injection (50 mgakg i.p.) in AP-X and SHAM rats At the high dose tested, amylin (50 mgakg i.p.) produced a signi®cant reduction in cumulative food intake in SHAM rats and, although with a signi®cantly lower potency (P`0.01 (1 h) and P`0.05 (2 h), respectively), amylin also reduced feeding in AP-X rats ( Figure 3 ).
Experiment 4: effect of sCT on food intake and body weight after single sCT injection (0.5, 5 or 50 mgakg i.p.) in AP-X and SHAM rats In SHAM rats, sCT signi®cantly reduced cumulative food intake at all doses tested (0.5, 5 and 50 mgakg; Table 3 ). While the anorectic effect of the low (0.5 mgakg) and moderate (5 mgakg) dose of sCT was completely abolished in AP-X rats, sCT administered at the high dose (50 mgakg) signi®-cantly reduced food intake in AP-X rats ( Table 3 ). The latter effect was however signi®cantly attenuated compared with SHAM rats (P`0.001 at all time points). Similar to the observations in a recent study, 15 sCT's anorectic effect had a long duration. This was evident in SHAM and in AP-X rats (cumulative food intake during the ®rst 24 h after injection: SHAM rats NaCl 29.6 AE 1.1 g vs sCT 4.5 AE 0.6 g (P`0.001); AP-X rats NaCl 29.3 AE 1.4 g vs sCT 18.6 AE 2.8 g (P`0.001); signi®cant attenuation of sCT's effect by APaNTS lesion (P`0.001)).
Discussion
The present study demonstrates for the ®rst time that, unlike intact rats, rats with a lesion in the APaNTS region do not reduce food intake during chronic intraperitoneal infusion of amylin. Further, the sustained decrease in food intake induced by the chronic amylin infusion was associated with a reduction in body weight gain in intact rats while no such effect was observed in APaNTS lesioned rats. These results therefore underline the predominant role for neurons in the APaNTS region to mediate amylin's anorectic action because, Table 2 In¯uence of chronic intraperitoneal amylin infusion (2 mgakgah) on food intake in area postremaanucleus of the solitary tract lesioned (AP-X) and sham lesioned (SHAM) rats from days 7 to 14 of the infusion period (total 8 day food intake; average daily food intake; average dark phase food intake; average light phase food intake; average size of dark phase meals; average size of light phase meal; all measures in grams) SHAM rats AP-X rats NaCl Amylin NaCl Amylin b Signi®cant difference between amylin and NaCl within SHAM or AP-X rats, respectively (P`0.05; n 6 for all groups; Student ± Newman ± Keuls post hoc test). Figure 3 In¯uence of amylin (50 mgakg) injected i.p. at dark onset on cumulative food intake in 24 h food deprived area postremaanucleus of the solitary tract lesioned (AP-X; n 12) and sham lesioned (SHAM; n 12) rats compared with respective saline controls. * , ***Signi®cant difference between amylin-treated and respective control rats (ANOVA with paired Student's t-test as post hoc test; P`0.05 or 0.001, respectively). Table 3 In¯uence of acute intraperitoneal injection of salmon calcitonin (sCT; 0.5, 5 or 50 mgakg) injected at dark onset on cumulative food intake in area postremaanucleus of the solitary tract lesioned (AP-X) and sham lesioned (SHAM) rats compared with respective saline controls SHAM rats AP-X rats Dose (mgakg) NaCl sCT NaCl sCT 0.5 mgakg 1 h 9.0AE 0.6 5.2 AE 0.5** 6.6 AE 0.5 5.6 AE 0.7 2 h 11.7 AE 0.6 6.5 AE 0.6** 10.0 AE 0.8 9.9 AE 0.8 5 mgakg 1 h 9.3AE 0.4 3.7 AE 0.7** 6.9 AE 0. APaNTS lesion abolishes amylin's chronic anorectic effect TA Lutz et al in addition to the short-term anorectic effect of amylin injected i.p. (5 mgakg; 3, 11), the sustained effect of amylin on food intake (and body weight) induced by a chronic infusion also seems to be mediated by the APaNTS region. Experiments 3 and 4 showed, however, that when a high dose of amylin or its receptor agonist sCT (50 mgakg) was injected, some anorectic response could also be elicited in APaNTS lesioned rats. Hence, receptors outside the APaNTS region, possibly in the forebrain, also seem to play some role in mediating peripheral amylin's anorectic effect. According to previous studies, there is no doubt that the short-term anorectic effect of amylin which is induced by the i.p. injection of a low to moderate amylin dose is mediated by neurons in the APaNTS region. First, a lesion in the APaNTS region abolished amylin's anorectic effect after i.p. injection 3, 11 while deafferentiation with the neurotoxin capsaicin did not affect the anorectic effect of amylin. 4, 12 Second, anorectic doses of amylin have been shown to induce c-Fos expression in the APaNTS region. 17 ± 19 While c-Fos expression was also induced in forebrain areas involved in the control of food intake such as the central nucleus of the amygdala, the lateral parabrachial nucleus and the paraventricular nucleus of the hypothalamus in intact rats, c-Fos expression in these brain sites was markedly reduced in AP-X rats. 19, 20 The APaNTS region therefore seems to be the major target for circulating amylin to elicit its anorectic effect. Finally, recent electrophysiological studies showed that physiological postprandial concentrations of amylin increase the ®ring rate of AP neurons. 17 We originally hypothesized that, while AP neurons are the primary targets for the short-term anorectic effect of peripheral amylin, 3, 11 this role may also be adopted by amylin receptors located at other brain sites as mediators of the sustained anorectic effect of amylin induced by chronically elevated amylin levels. The present study shows that, at least at low to moderate doses, APaNTS neurons play a predominant role for the anorectic effect of peripheral amylin because the APaNTS lesion completely blocked the anorectic effect of amylin induced by chronic i.p. amylin delivery. Our study also shows, however, that when high doses of amylin or its receptor agonist sCT are administered, some anorectic response can also be elicited in APaNTS lesioned rats. Although it cannot be completely excluded that some remnant amylin receptors in the AP are responsible for this effect, it is more likely that amylin receptors at other brain sites, which mediate amylin's anorectic effect after central administration, 5, 11 may also come into play for peripheral amylin's effect. Therefore, while the APaNTS region seems to play the major role in mediating the acute 3, 11 and chronic (present study) anorectic effects of peripheral amylin, amylin receptors at other brain sites may also mediate some part of the anorectic effect of peripheral amylin, at least when amylin levels are highly elevated. It is possible, for example that activation of the latter amylin receptors contributes to cancer anorexia occurring during certain neoplastic diseases of the pancreas which are associated with highly and chronically elevated plasma amylin levels. 21 The sustained anorectic effect induced by chronic amylin infusion was associated with a reduction in body weight gain in SHAM rats while body weight gain in AP-X rats was not lower in amylin-treated than in control rats. In fact, throughout the whole study amylin rather tended to increase food intake slightly in AP-X rats when compared to saline treated AP-X controls. At some time points during the infusion, this effect was signi®cant. The slightly higher food intake in amylin-treated AP-X rats also resulted in a slightly higher rate of body weight gain in these rats compared to saline-treated controls.
The reason for the slight increase in feeding (and body weight gain) induced by amylin infusion in AP-X rats is unknown. It is however possible that this effect is related to amylin's inhibitory effect on pancreatic insulin secretion. 10, 22, 23 Because insulin, besides leptin, seems to be an important lipostatic long-term regulator of food intake and body weight, 8 the inhibitory effect of amylin on insulin secretion may perhaps lead to a disinhibition of feeding in AP-X rats due to the reduced insulin effect in the hypothalamus. It is supposed that this (indirect) effect of amylin in AP-X rats to increase feeding via an inhibition of insulin secretion is overrun in intact animals by amylin's direct effect of AP neurons to decrease food intake. The idea that the slight increase in food intake and meal size in amylintreated AP-X rats is due to diminished insulin secretion and disinhibition of feeding is in line with a recent study showing that a blockade of endogenous insulin by insulin antibodies leads to an increase in meal size. 24 The sustained anorectic effect induced by chronic amylin infusion observed in the present study is consistent with a series of previous studies. 6, 7 Interestingly, however, in our study, amylin appeared to reduce food intake mainly by reducing the average size of meals consumed during the dark phase in intact rats. This is in contrast to previous studies 6, 7 showing a reduction in total food intake mainly via a reduction of meal number with meal size being unaffected. Further, in one of the former studies, 6 amylin reduced dark phase and light phase food intake while in the present study, the effect of amylin was mostly limited to decreasing dark phase food intake. The reason for the differences in amylin's effect on meal pattern between the previous 6,7 and our studies is unknown. The amylin dose used in the present study was similar to the doses used in the previous studies, and rats were of similar body weight. It is unknown if the use of different rat strains, different diets or the route of administration (s.c. 6 or i.v. 7 vs i.p.) underlies the differing effects of amylin on meal pattern.
To summarize, the present study corroborates the idea that amylin, in addition to its function as a short-term satiety hormone, 1 also plays an important role in the long term regulation of food intake and maintenance of body weight. 5 Amylin and insulin have been shown to synergistically reduce food intake in rats, 5 but it remains to be clari®ed where and how amylin interacts with the lipostatic signal insulin (and with leptin) in controling food intake. Amylin's long term effect on food intake and its effect on body weight also appear to mainly depend on an intact APaNTS region. Since a high dose of amylin and its receptor agonist sCT, however, produced some anorectic effect in rats lesioned in the APaNTS region, amylin receptors outside the APaNTS area 13 also seem to play some role in the control of food intake by circulating amylin.
